Skip to content

The Intraoperative Landiolol for Intracranial Aneurysm Surgery Trials

The Intraoperative Landiolol for Intracranial Aneurysm Surgery Trials - ILAST (The Intraoperative Landiolol for Intracranial Aneurysm Surgery Trials)

Status
Active, not recruiting
Phases
Phase 4
Study type
Interventional
Source
JPRN
Registry ID
JPRN-UMIN000000945
Enrollment
60
Registered
2007-12-15
Start date
2005-01-01
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Tachyarrhythmia

Interventions

Landiolol hydrochloride is continuously administered during the operation. Heart rate is maintained betweeb 60 and 80bpm. Landiolol hydrochloride is not used regardless of any heart rate. If neces

Sponsors

The Intraoperative Landiolol for Intracranial Aneurysm Surgery Trials Group
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1. Patients undergoing ruptured intraclanial aneurysm surgery. 2. The interval from the onset of symptoms until the operation is less than 48 hours. 3.Heart rate is 90 or more beats per minute before the operation.

Exclusion criteria

Exclusion criteria: 1.Patients with a cardiogenic shock, congestive heart failure, or hypotension (systolic blood pressure less than 90 mmHg, more than 30 minutes) 2. Patients with a diabetic ketoacidosis, or serious metabolic acidosis(BE equal or less than -10) 3. Patients with an atrioventricular block (the degree of II or III) or sick sinus syndrome. 4. Pregnant. 5. Patients with preoperative poor neurological score(Hunt and Kosnik grade 5). 6. Patients with a renal failure or undergoing hemodialysis. 7. Patients with a severe hepatic insufficiency. 8. Patients with severe obesity(body mass index equal or more than 35). 9. Patients with an immunodeficiency or medicated with the immunosuppressant. 10. Patients with an infection, such as a hepatitis B virus, a hepatitis C virus or human immunodeficiency virus, before the operation

Design outcomes

Primary

MeasureTime frame
The incidence of cardiovascular event

Secondary

MeasureTime frame
Heart rate Plasma cytokine Markers of tissue damage (blood nitrotyrosine, urine 80HdG, S100-beta) Incidence of delayed ischemic neuronal deficits Neurological prognosis after three months

Countries

Japan

Contacts

Public ContactMasahiko Kawaguchi

Nara Medical University Department of Anesthesiology

drjkawa@naramed-u.ac.jp0744-29-8902

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026